Optiscan is featured in Stockhead for our innovative platform that enhances cancer surgery outcomes. The article highlights how Optiscan’s technology enables real-time collaboration between surgeons and pathologists, allowing immediate, on-the-spot diagnoses at the cellular level. This breakthrough reduces the need for follow-up surgeries and improves patient outcomes. CEO Dr. Camile Farah emphasizes the potential of this technology to revolutionize cancer treatment through precision surgery and digital pathology.

Read the full article here.